Lantern Pharma (NASDAQ: LTRN) reported its second-quarter 2026 operational and financial results, underscoring significant advancements in its AI-driven oncology pipeline and the strategic establishment of Open Medicine AI (“OMAI”) as a separate company. The company’s focus on leveraging artificial intelligence and its proprietary RADR® platform continues to yield promising clinical and regulatory developments.
One of the key highlights is the emerging data from the Phase 2 HARMONIC™ trial, which showed that LP-300’s progression-free survival benefit deepened with treatment duration in patients with EGFR exon 21 L858R mutations. This finding is particularly relevant for never-smoker patients with relapsed advanced lung adenocarcinoma who have undergone TKI treatment. The FDA reviewed key protocol amendments without objection, signaling potential alignment on the trial’s design and endpoints. Additionally, the European Medicines Agency cleared an investigator-initiated Phase 1b/2 trial of LP-184, also known as zirdafulven, in biomarker-selected advanced bladder cancer. This milestone expands the clinical development of LP-184 beyond its current focus on pediatric CNS cancers through Starlight Therapeutics.
In a strategic move, Lantern established Open Medicine AI as a wholly owned subsidiary in August and entered into board-approved commercial licensing agreements for its multi-agentic AI co-scientist platform, previously launched as withZeta.ai. This platform, now commercially available as a subscription-based research tool for the global biomedical and drug development community, represents a new revenue stream for the company. The spin-off of OMAI is aimed at maximizing the value of this AI technology, which has the potential to accelerate drug discovery and development across the industry.
Financially, Lantern reported a second-quarter loss from operations of approximately $3.5 million, down about 25% from $4.7 million in the same period last year. Research and development expenses declined 42% to approximately $1.8 million, reflecting disciplined cost management. The net loss was approximately $7.1 million, or $0.57 per share, compared with $4.3 million, or $0.40 per share, in the prior year. The increase in net loss was largely due to approximately $3.6 million in warrant-related expense. As of June 30, 2026, the company held cash, cash equivalents, and marketable securities totaling approximately $7.4 million, providing a runway to support ongoing clinical trials and operational activities.
The U.S. Patent and Trademark Office issued a Notice of Allowance covering a three-gene patient-selection signature for LP-184, which strengthens the company’s intellectual property portfolio and supports the precision medicine approach of its pipeline. This signature is designed to identify patients most likely to benefit from LP-184, potentially improving trial success rates and therapeutic outcomes.
Lantern Pharma’s advancements are part of a broader trend in oncology where AI-driven platforms are increasingly used to optimize drug development. The establishment of Open Medicine AI as a separate entity highlights the growing value of such platforms in the biomedical sector. With a robust pipeline and strategic initiatives, Lantern is positioning itself to address significant unmet needs in cancer treatment.
For more details on the full press release, visit https://nnw.fm/m9pULA.
